A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Purpose Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study examined the safety, tolerability, pharmacokinetics and maximum tolerated dose (MTD) of PICN alone and in combination with carboplatin. Its early...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology Vol. 87; no. 6; pp. 779 - 788
Main Authors: Ma, Wen Wee, Zhu, Mojun, Lam, Elaine T., Diamond, Jennifer R., Dy, Grace K., Fisher, George A., Goff, Laura Williams, Alberts, Steven, Bui, Lynne A., Sanghal, Akhil, Kothekar, Mudgal, Khopade, Ajay, Chimote, Geetanjali, Faulkner, Robert, Eckhardt, S. Gail, Adjei, Alex A., Jimeno, Antonio
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2021
Springer Nature B.V
Subjects:
Anticancer properties
Antitumor activity
Biliary tract
Cancer
Cancer Research
Carboplatin
Cholangiocarcinoma
Dispersion
Evaluation
Exposure
Hypersensitivity
Injection
Medicine
Medicine & Public Health
Nanotechnology
Neutropenia
Oncology
Original Article
Overdose
Paclitaxel
Peripheral neuropathy
Pharmacokinetics
Pharmacology
Pharmacology/Toxicology
Safety
Solid tumors
Toxicity
Tumors
Carboplatin
Phase I
Pharmacokinetics
Biliary tract cancer
Paclitaxel
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Paclitaxel injection concentrate for nano-dispersion (PICN) is a Cremophor-free, nanotechnology-driven paclitaxel formulation. This phase I study examined the safety, tolerability, pharmacokinetics and maximum tolerated dose (MTD) of PICN alone and in combination with carboplatin. Its early efficacy in unresectable biliary tract cancers (BTCs) was also evaluated. Methods This multi-center study comprised two parts. Part A contained a dose-escalation cohort following “3 + 3” design using PICN monotherapy in advanced solid tumors (Part A1); Part A2 dose-expansion cohort was then conducted in advanced BTCs due to observed efficacy in Part A1. Part B1 and B2 evaluated escalating dose of PICN with carboplatin in advanced solid tumors. PICN was administered as a 30 min-infusion every 3 weeks without pre-medications for hypersensitivity reactions. Results Thirty-six patients received PICN monotherapy in Part A and 21 received PICN plus carboplatin in Part B. The MTD of PICN was determined to be 295 mg/m 2 both as a monotherapy and in combination with carboplatin at AUC 5. Dose-proportional exposure in paclitaxel C max and AUC was observed overdose range from 175 to 325 mg/m 2 for PICN monotherapy and its combination with carboplatin. Carboplatin did not alter PICN exposure. Clinically significant toxicities mainly include neutropenia and peripheral neuropathy. PICN monotherapy yielded a response rate of 20% in unresectable BTCs. Conclusion This study demonstrated the safety and stable pharmacokinetics of PICN as a monotherapy and in combination with carboplatin. Single-agent PICN showed promising antitumor activity in advanced BTCs, warranting further studies to investigate its role in gastrointestinal cancers.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-021-04235-z